|
Quotes & Info
|
| PLX > SEC Filings for PLX > Form 8-K on 7-Mar-2013 | All Recent SEC Filings |
7-Mar-2013
Other Events
On March 7, 2013, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that it has received approval from the Israeli Ministry of Health to initiate a phase I clinical trial of PRX-112, or Oral GCD, the Company's orally-administered product candidate for the treatment of Gaucher disease. A copy of the press release is filed as Exhibit 99.1.
|
|